An overview of currently available anti-insulin-like growth factor I receptor antibodies.

A number of studies during the last two decades revealed that the insulin-like growth factor I receptor (IGFIR) is an attractive target for cancer molecular therapy. Different molecular strategies have been developed and evaluated in experimental systems, and one such strategy involves anti-IGFIR antibodies, which have been rigorously tested for their therapeutic potential over the last 5-6 years. This mini-review thus introduces currently available IGFIR antibodies with a particular emphasis on epitope mapping and anti-IGFIR antibody-induced cancer growth inhibition.